FCMI
Foresite Capital Management II Portfolio holdings
AUM
$29.2M
This Quarter Return
+1.97%
1 Year Return
+44.84%
3 Year Return
-66.21%
5 Year Return
-37.37%
10 Year Return
–
AUM
$263M
AUM Growth
+$263M
(-6.6%)
Cap. Flow
-$22.2M
Cap. Flow
% of AUM
-8.45%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
2
Top Buys
No buys this quarter
Top Sells
| 1 |
Novavax
NVAX
|
$14M |
| 2 |
XLRN
Acceleron Pharma Inc.
XLRN
|
$7.9M |
| 3 |
EPZM
Epizyme, Inc
EPZM
|
$356K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
10x Genomics
TXG
$1.74B
| $261M | 99.34% | 1,753,528 | – | – |
|
|
EPZM
2
DELISTED
Epizyme, Inc
EPZM
| $1.73M | 0.66% | 690,002 -142,334 | -17% | -$356K |
|
|
3
Novavax
NVAX
$1.21B
| – | – | -67,373 | Closed | -$14M |
|
|
XLRN
4
DELISTED
Acceleron Pharma Inc.
XLRN
| – | – | -45,884 | Closed | -$7.9M |
|